Published in Science on September 13, 2013
Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol (2014) 2.10
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci U S A (2014) 1.37
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano (2014) 0.99
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest (2015) 0.97
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure (2015) 0.95
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest (2016) 0.92
Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing. Angew Chem Int Ed Engl (2015) 0.91
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol (2016) 0.91
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines (2014) 0.91
Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. Nat Commun (2016) 0.90
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol (2014) 0.89
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLoS One (2015) 0.89
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88
Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy. Curr Pharm Des (2014) 0.88
Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci U S A (2014) 0.87
Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget (2015) 0.87
Putting together structures of epidermal growth factor receptors. Curr Opin Struct Biol (2014) 0.86
Improving the accuracy of the structure prediction of the third hypervariable loop of the heavy chains of antibodies. Bioinformatics (2014) 0.86
Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed Res Int (2014) 0.85
Antibody-based imaging strategies for cancer. Cancer Metastasis Rev (2014) 0.84
CCN: core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget (2016) 0.84
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res (2016) 0.84
AB-Bind: Antibody binding mutational database for computational affinity predictions. Protein Sci (2015) 0.84
Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnol (2015) 0.83
A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway. Clin Exp Metastasis (2014) 0.83
Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn (2014) 0.83
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells. Chembiochem (2014) 0.83
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharm Res (2014) 0.83
Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget (2015) 0.82
Automated antibody structure prediction using Accelrys tools: results and best practices. Proteins (2014) 0.82
Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics (2015) 0.82
Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget (2014) 0.82
A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc Natl Acad Sci U S A (2014) 0.81
Targeted nanotherapeutics in cancer. Int J Nanomedicine (2014) 0.81
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology (2015) 0.81
Direct analysis of mAb aggregates in mammalian cell culture supernatant. BMC Biotechnol (2014) 0.81
Peptide aptamers: development and applications. Curr Top Med Chem (2015) 0.80
A novel screening method to assess developability of antibody-like molecules. MAbs (2015) 0.80
Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol (2014) 0.80
Vaccine for human contraception targeting sperm Izumo protein and YLP12 dodecamer peptide. Protein Sci (2014) 0.80
A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS One (2014) 0.80
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res (2016) 0.80
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat (2016) 0.79
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol (2015) 0.79
Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth Biol (2014) 0.79
Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics. PLoS One (2015) 0.79
Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab. MAbs (2014) 0.79
Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Cancer Med (2014) 0.79
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET. Eur J Nucl Med Mol Imaging (2016) 0.78
Influence of immunoglobulin isotype on therapeutic antibody function. Blood (2016) 0.78
Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease. J Biol Chem (2015) 0.78
Complement in monoclonal antibody therapy of cancer. Immunol Res (2014) 0.78
Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays. ACS Cent Sci (2015) 0.78
Effects of an amyloid-beta 1-42 oligomers antibody screened from a phage display library in APP/PS1 transgenic mice. Brain Res (2016) 0.78
Advances in Anticancer Protein Delivery Using Micro-/ Nanoparticles. Part Part Syst Charact (2014) 0.77
Epidermal growth factor receptor-coamplified and overexpressed protein (VOPP1) is a putative oncogene in gastric cancer. Clin Exp Med (2014) 0.77
Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers. Biochemistry (2014) 0.77
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget (2015) 0.77
Mild hyperthermia influence on Herceptin(®) properties. Radiol Oncol (2015) 0.77
A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. J Biol Chem (2015) 0.77
Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene (2016) 0.77
Ligand-targeted theranostic nanomedicines against cancer. J Control Release (2016) 0.77
Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling. Sci Rep (2014) 0.77
Dissecting antibodies with regards to linear and conformational epitopes. PLoS One (2015) 0.77
Targeted gene suppression by inducing de novo DNA methylation in the gene promoter. Epigenetics Chromatin (2014) 0.77
Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Vet Sci (2015) 0.76
Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells. Eur J Med Res (2014) 0.76
Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts. Springerplus (2015) 0.76
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs (2015) 0.76
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab. Oncoimmunology (2015) 0.76
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep (2016) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Aptamer-conjugated live human immune cell based biosensors for the accurate detection of C-reactive protein. Sci Rep (2016) 0.75
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo. Oncoimmunology (2016) 0.75
Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials (2014) 0.75
Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells. Oncotarget (2016) 0.75
Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells. Oncotarget (2016) 0.75
A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening. J Biomol Screen (2015) 0.75
Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues. Int J Mol Sci (2016) 0.75
Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. Int J Med Sci (2016) 0.75
Targeting of non-cycling cells of hypoxic tumors. Cell Cycle (2016) 0.75
Analysis of antibody aggregate content at extremely high concentrations using sedimentation velocity with a novel interference optics. PLoS One (2015) 0.75
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. J Cancer Res Clin Oncol (2015) 0.75
l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies. Mol Imaging (2016) 0.75
Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis. BMC Immunol (2017) 0.75
A novel and effective cancer immunotherapy mouse model using antigen-specific B cells selected in vitro. PLoS One (2014) 0.75
A comparison of biophysical characterization techniques in predicting monoclonal antibody stability. MAbs (2016) 0.75
IgE immunotherapy against cancer. Curr Top Microbiol Immunol (2015) 0.75
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol (2005) 5.97
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 4.12
Recycling endosomes can serve as intermediates during transport from the Golgi to the plasma membrane of MDCK cells. J Cell Biol (2004) 3.82
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity (2007) 3.58
Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature (2010) 3.52
Activation of lysosomal function during dendritic cell maturation. Science (2003) 3.22
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature (2002) 3.21
Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol (2008) 2.82
The AP-1A and AP-1B clathrin adaptor complexes define biochemically and functionally distinct membrane domains. J Cell Biol (2003) 2.78
Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature (2006) 2.64
Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nat Cell Biol (2004) 2.59
The Rab8 GTPase selectively regulates AP-1B-dependent basolateral transport in polarized Madin-Darby canine kidney cells. J Cell Biol (2003) 2.39
Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell (2005) 2.35
Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. Dev Cell (2010) 2.25
Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med (2003) 2.16
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Immunotherapy: bewitched, bothered, and bewildered no more. Science (2004) 1.99
Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med (2006) 1.77
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine (2009) 1.72
Transferrin receptor recycling in the absence of perinuclear recycling endosomes. J Cell Biol (2002) 1.62
Rab10 is involved in basolateral transport in polarized Madin-Darby canine kidney cells. Traffic (2006) 1.61
MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural regulatory T cells. J Exp Med (2013) 1.57
How the rich get richer. J Cell Biol (2007) 1.57
A hierarchy of signals regulates entry of membrane proteins into the ciliary membrane domain in epithelial cells. J Cell Biol (2011) 1.52
Par3 functions in the biogenesis of the primary cilium in polarized epithelial cells. J Cell Biol (2007) 1.51
Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A (2010) 1.45
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
Host ER-parasitophorous vacuole interaction provides a route of entry for antigen cross-presentation in Toxoplasma gondii-infected dendritic cells. J Exp Med (2009) 1.42
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A (2002) 1.38
How the rich get richer. J Exp Med (2007) 1.38
By the scientists, for the scientists. J Cell Biol (2009) 1.37
Membrane proteins follow multiple pathways to the basolateral cell surface in polarized epithelial cells. J Cell Biol (2009) 1.31
A33 antigen displays persistent surface expression. Cancer Immunol Immunother (2008) 1.26
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 1.25
CHMP5 is essential for late endosome function and down-regulation of receptor signaling during mouse embryogenesis. J Cell Biol (2006) 1.25
Essential and unique roles of PIP5K-gamma and -alpha in Fcgamma receptor-mediated phagocytosis. J Cell Biol (2009) 1.23
Modulation of cell adhesion and motility in the immune system by Myo1f. Science (2006) 1.22
The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface. Proc Natl Acad Sci U S A (2006) 1.22
Hsc70 is required for endocytosis and clathrin function in Drosophila. J Cell Biol (2002) 1.21
The J-domain protein Rme-8 interacts with Hsc70 to control clathrin-dependent endocytosis in Drosophila. J Cell Biol (2004) 1.16
Influenza A virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells. PLoS Pathog (2012) 1.14
Vectorial insertion of apical and basolateral membrane proteins in polarized epithelial cells revealed by quantitative 3D live cell imaging. J Cell Biol (2006) 1.13
Transcytosis of NgCAM in epithelial cells reflects differential signal recognition on the endocytic and secretory pathways. J Cell Biol (2005) 1.12
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia (2007) 1.12
Actin dependence of polarized receptor recycling in Madin-Darby canine kidney cell endosomes. Mol Biol Cell (2002) 1.11
Differential recognition of tyrosine-based basolateral signals by AP-1B subunit mu1B in polarized epithelial cells. Mol Biol Cell (2002) 1.09
The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J (2005) 1.07
AMP-activated protein kinase (AMPK) activation and glycogen synthase kinase-3β (GSK-3β) inhibition induce Ca2+-independent deposition of tight junction components at the plasma membrane. J Biol Chem (2011) 1.03
Spinophilin participates in information transfer at immunological synapses. J Cell Biol (2008) 1.01
Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. J Cell Biol (2012) 1.00
Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLoS One (2010) 1.00
IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci U S A (2004) 1.00
Trafficking guidance receptors. Cold Spring Harb Perspect Biol (2010) 0.99
MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain length. Proc Natl Acad Sci U S A (2012) 0.99
β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells. J Leukoc Biol (2013) 0.98
A PDZ-binding motif controls basolateral targeting of syndecan-1 along the biosynthetic pathway in polarized epithelial cells. Traffic (2008) 0.96
Harnessing dendritic cells for immunotherapy. Semin Immunol (2011) 0.95
Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin. Cell Microbiol (2008) 0.95
Sorting of H,K-ATPase beta-subunit in MDCK and LLC-PK cells is independent of mu 1B adaptin expression. Traffic (2004) 0.90
Differential role of the Ca(2+) sensor synaptotagmin VII in macrophages and dendritic cells. Immunobiology (2009) 0.90
Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) (2008) 0.89
Regulated recruitment of MHC class II and costimulatory molecules to lipid rafts in dendritic cells. J Immunol (2004) 0.88
Old lysosomes, new tricks: MHC II dynamics in DCs. Trends Immunol (2005) 0.87
Targeting antigen to CD19 on B cells efficiently activates T cells. Int Immunol (2005) 0.85
Ira Mellman: from endosomes to industry. Interview by William A Wells. J Cell Biol (2007) 0.85
Immunotherapy: The path to win the war on cancer? Cell (2015) 0.84
Computational cell biology. J Cell Biol (2003) 0.82
The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. J Immunol (2002) 0.80
Antigen processing and presentation. Curr Opin Immunol (2010) 0.79
Presentation of self-antigens on MHC class II molecules during dendritic cell maturation. Int Immunol (2005) 0.79
Hepatocyte Growth Factor stimulated cell scattering requires ERK and Cdc42-dependent tight junction disassembly. Biochem Biophys Res Commun (2010) 0.78
Ralph Steinman (1943-2011). Nature (2011) 0.78
Remembering Ralph Steinman. J Exp Med (2011) 0.76
Incomplete screening? Nat Immunol (2007) 0.75
Profile of Ira Mellman. Interview by Prashant Nair. Proc Natl Acad Sci U S A (2012) 0.75
Single-molecule optical methods analyzing receptor tyrosine kinase activation in living cells. Methods Mol Biol (2015) 0.75
The JEM and the JCB: a synergistic partnership. J Cell Biol (2004) 0.75